Castle Creek finalizes exclusive license agreement for Arlevert

Castle Creek Pharmaceuticals' exclusive license agreement for the rights to Arlevert in the United States has been finalized.
Castle Creek will receive the rights to Arlevert, which is a fixed-dose oral combination, from Hannig Arzneimittel GmbH & Co. KG. Arlevert has already been approved by a number of countries in the European Union, where it is used to treat vertigo.
“We are very pleased to license Arlevert for the U.S., as vertigo is a complex problem, and combining two molecules with different modes of action could be important for addressing both the peripheral and central effects of vertigo,” Castle Creek Pharmaceuticals President and Chief Scientific Officer Dr. Greg Licholai said. “Our goal is to expedite the development of Arlevert in the U.S. by building on the European patient experience of over 11 million prescribed doses and its track record of effectiveness, safety and tolerability. Arlevert will be an important addition to our pipeline, as it addresses a significant need for patients who suffer from the debilitating effects of vertigo.”
In previous clinical trials, Arlevert has proved effective when treating vertigo compared to placebo, betahistine and the component mono-therapies. It has also proved well-tolerated with minimum sedation.